

The following information is not legal or regulatory advice and is only intended to provide preliminary colour. This information is provided by UBS in good faith, based on information available at the time of writing, however, we make no representation as to its accuracy, completeness or appropriateness. Due to the complex and technical nature of regulation, clients should consult with their own legal counsel, and should not rely on any of the information contained herein.

Overview of UBS Exchange Traded Commodities (ETCs)

Information on UBS ETCs within a UCITS framework

Background and Overview

The purpose of this Overview is to provide information about the UBS Exchange Traded Commodities (UBS ETCs) in the context of potential UCITS eligibility. UBS ETCs are delta-1 products listed on various exchanges across Europe including SIX Swiss Exchange, London Stock Exchange and Borsa Italiana. Each UBS ETC provides exposure to either a) a distinct commodity future; b) a single commodity index/strategy; or c) a basket of commodity futures and/or commodity indices/strategies.

For information related to the Luxembourg law, the information provided is in reference inter alia to the Law of 17 December 2010 relating to undertakings for collective investment (the 2010 Law), the Grand Ducal Regulation of 8 February 2008 (the Grand-Ducal Regulation) and the ESMA Guidelines 2014/937 on ETFs and other UCITS issues. For information related to the Irish law, the information provided is in reference to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011, as amended and the Central Bank of Ireland guidance which is available at:

<https://www.centralbank.ie/regulation/industry-market-sectors/funds/ucits/guidance>.

We understand that under both Luxembourg and Irish law, certain transferable securities which are listed on regulated exchanges are considered eligible assets for a UCITS. Our assumption is that under these guidelines,

UBS ETCs could be considered as transferable securities based on the following criteria:

- a) the potential loss which the UCITS may incur with respect to holding those instruments is limited to the amount paid for them;
- b) their liquidity does not compromise the ability of the UCITS to comply with its obligation to provide at least fortnightly redemption facilities;
- c) reliable valuations will be available as the Notes will be listed and quoted on a regulated market;
- d) appropriate information will be available as the Notes are listed and quoted on a regulated market;
- e) they are negotiable;
- f) their acquisition is consistent with the investment objectives or the investment policy, or both, of the UCITS;
- g) their risks are adequately captured by the risk management process of the UCITS; and
- h) they do not embed any derivatives.

Diversification

As an additional consideration for investors in the UBS ETCs, we understand that a UCITS may invest no more than 10% of its assets in transferable securities or money market instruments issued by the same body. The total value of the transferable securities and money market instruments held by a UCITS in the issuing bodies in each of which it invests more than 5% of its assets shall not exceed 40% of the value of its assets.

The following information is not legal or regulatory advice and is only intended to provide preliminary colour. This information is provided by UBS in good faith, based on information available at the time of writing, however, we make no representation as to its accuracy, completeness or appropriateness. Due to the complex and technical nature of regulation, clients should consult with their own legal counsel, and should not rely on any of the information contained herein.

Overview of UBS Exchange Traded Commodities (ETCs)

Please see summary below for UBS ETCs with respect to the criteria for transferable securities:

- a. the potential loss which the UCITS may incur with respect to holding those instruments is limited to the amount paid for them;

UBS ETCs are delta-1 securities that provide 1-1 exposure to the underlying. Each of the UBS ETCs, have a minimum value of zero, meaning that holders thereof cannot lose more than the purchase price of such UBS ETC.

- b. their liquidity does not compromise the ability of the UCITS to comply with its obligation to provide at least fortnightly redemption facilities;

Each UBS ETC is listed on a regulated exchange such as the SIX Swiss Exchange, London Stock Exchange, or Borsa Italiana. UBS as issuer provides daily levels of each security and can provide a secondary market upon request from clients under normal market conditions. Note that UBS ETCs provide a delta-1 exposure to the underlying commodity/basket and hence liquidity is driven by the underlying commodities markets which are highly liquid.

- c. reliable valuation is available for them

Daily secondary market levels are available via the exchange. Levels are also provided by UBS via Bloomberg and/or Keyinvest.

- d. appropriate information is available for them

ETCs are exchange listed. Comprehensive information is available on Bloomberg and/or www.ubs.com/keyinvest and/or www.ubs.com/cmci.

- e. they are negotiable;

The ETCs are issued in dematerialized book entry securities and as such are fully negotiable.

- f. their acquisition is consistent with the investment objectives or the investment policy, or both, of the UCITS;

This determination should be made by the UCITS.

- g. their risks are adequately captured by the risk management process of the UCITS.

This determination should be made by the UCITS.

- h. The notes should not embed any derivatives

The ETCs provide a one-to-one exposure to a) a distinct commodity future; b) a single commodity index/strategy; or c) a basket of commodity futures and/or commodity indices/strategies.

Corporate Communications Disclaimer

This material has been issued by UBS AG and/or any of its affiliates ("UBS" and "we", "us"). The securities, derivatives or other financial instruments described herein ("Instruments") may not be eligible for sale in all jurisdictions or to certain categories of investors. This material is for distribution only under such circumstances as may be permitted by applicable law, rules and/or regulations. All communications between you and us may be monitored. Please see further details as set out under "Country-specific information" below.

Provenance and purpose: This material has been prepared by sales or trading personnel and it is not a product of our Research Department and is not intended to recommend, suggest or inform an investment strategy. Opinions expressed may differ from the opinions expressed by our other divisions, including those of the Research Department.

Recipient to exercise own judgment: The information contained herein should not be regarded by recipients as a substitute for the exercise of their own judgment. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute the provision of investment advice. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions.

Not an offer to transact: This material has been prepared for informational purposes only and is not an offer to buy or sell or a solicitation of an offer to buy or sell any Instrument or to participate in any particular trading strategy. This material is not an official confirmation of terms.

Conflicts of Interest: This material may contain proprietary commentary produced in conjunction with our trading desks that trade as principal in the Instruments. This commentary may therefore not be independent from our proprietary interests or those of connected parties which may conflict with your interests. We may have accumulated or may acquire a long or short position in the subject Instrument, or derivative thereof, on the basis of this material prior to its dissemination.

We may trade as principal or otherwise act or have acted as market-maker and/or as an execution venue in the Instruments. Instruments may be highly illiquid which may adversely impact the price, spread and speed of execution of orders in those Instruments. Furthermore, we may have or have had a relationship with or may provide or have provided investment banking, capital markets and/or other financial services to the companies associated with the Instruments.

We have policies and procedures designed to manage conflicts of interest. In order to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS, we may rely on information barriers. Additional information can be found at "<https://www.ubs.com/global/en/investment-bank/regulatory.html>" and may be made available upon request.

Contents of Material: This material is prepared from information believed to be reliable, but we make no representations or warranties, express or implied, and owe no duties (including in negligence) as to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the Instruments, markets or developments referred to in the materials. The information contained in this material is as of the date hereof only and is subject to change without notice. We do not undertake any obligation to update this material. Any prices or quotations contained herein are indicative only and are not for valuation purposes. Past performance is not necessarily indicative of future results.

Statement of Risk: The Instruments are not suitable for all investors, and trading in these Instruments is considered risky and is appropriate only for sophisticated investors and in particular any target market identified herein. These Instruments may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates, foreign exchange rates and other market conditions. Some Instruments may be physically settled or cash settled.

No Liability: To the fullest extent permitted by law, neither we nor any of our directors, employees or agents is liable for any loss (including indirect, special or consequential losses or damages, and even if we have been advised of the possibility of loss) arising out of any person's use of, or reliance upon, the information contained herein.

Securities Act: Any Instruments that have not been registered under the United States Securities Act of 1933 may not be offered or sold in the United States except pursuant to an exception from the registration requirements of the Securities Act and applicable state securities laws and in such circumstances as may be permitted by applicable law.

No redistribution or reproduction: We specifically prohibit the redistribution or reproduction of this material in whole or in part without our prior written permission and we accept no liability whatsoever for the actions of third parties in this respect. © UBS 2018. All rights reserved.

Country-specific information: Except as otherwise specified herein, these materials are distributed to professional clients only, and are not suitable for retail clients.

For further important country-specific information, please see the following link: <https://www.ubs.com/global/en/investment-bank/us-sales-trading-country-specific.html>